Regeneron Pharmaceuticals, Inc.
REGN
$957.00
$19.392.07%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -1.97% | 13.06% | 10.39% | 6.10% | -32.45% |
| Total Other Revenue | 66.41% | 64.25% | 17.06% | 23.40% | 48.14% |
| Total Revenue | 0.58% | 14.53% | 10.53% | 6.64% | -31.05% |
| Cost of Revenue | 6.98% | 22.99% | 36.54% | 24.83% | -7.94% |
| Gross Profit | -4.95% | 8.43% | -5.54% | -6.58% | -43.35% |
| SG&A Expenses | 11.69% | 21.05% | 36.89% | 33.58% | 18.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 92.42% | 98.91% | 96.55% | 97.52% | 58.23% |
| Total Operating Expenses | 8.66% | 25.65% | 38.14% | 28.64% | -1.17% |
| Operating Income | -14.78% | -1.04% | -22.22% | -22.06% | -56.22% |
| Income Before Tax | -13.37% | -26.43% | 12.43% | -19.14% | -47.08% |
| Income Tax Expenses | -109.40% | -46.93% | 3.06% | -54.11% | -53.50% |
| Earnings from Continuing Operations | -3.13% | -23.40% | 13.65% | -15.99% | -46.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.13% | -23.40% | 13.65% | -15.99% | -46.29% |
| EBIT | -14.78% | -1.04% | -22.22% | -22.06% | -56.22% |
| EBITDA | -12.61% | 0.01% | -18.95% | -19.00% | -53.77% |
| EPS Basic | -2.77% | -22.97% | 14.61% | -16.23% | -46.70% |
| Normalized Basic EPS | -11.79% | 7.34% | -15.16% | -17.27% | -52.98% |
| EPS Diluted | -2.87% | -23.76% | 13.79% | -16.72% | -46.71% |
| Normalized Diluted EPS | -11.97% | 6.17% | -15.80% | -17.70% | -52.96% |
| Average Basic Shares Outstanding | -0.37% | -0.56% | -0.83% | 0.28% | 0.75% |
| Average Diluted Shares Outstanding | -0.18% | 0.53% | -0.09% | 0.80% | 0.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
